https://www.selleckchem.com/pr....oducts/Dapagliflozin
This study aimed to develop and validate a bedside risk analysis system for predicting the clinical severity and prognosis of patients with COVID-19. A total of 444 COVID-19 patients were included and were randomly assigned into two groups at a ratio of 21 as derivation and validation groups. The new scoring system comprised of eight variables, which included history of having malignant diseases, history of having diabetes mellitus, dyspnea, respiratory rate of 24 bpm, C-reactive protein (CRP) of 14 mg/L, white blood cell
Like
Comment
Share
